Home/Biosimilar Atlas/Companies/SciGen

SciGen

Biosimilar developer, Australia. 1 development product across 1 molecule: somatropin.

First approval in the Atlas: Jun 2010, SciGen Biopharma (INN only), somatropin (CDSCO)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved1
EDEproducts registered0
Connections
1molecule1product1 of 7markets0candidates in trials5companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
SomatropinSciGen somatropin·····Jun 2010·1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with SciGen, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

BioPartnersOne shared molecule: somatropin2 molecules in its portfolioLG ChemOne shared molecule: somatropin2 molecules in its portfolioReliance Life SciencesOne shared molecule: somatropin14 molecules in its portfolioSandozOne shared molecule: somatropin10 molecules in its portfolioUSVOne shared molecule: somatropin3 molecules in its portfolio

Chronology

Compare SciGen with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.